Literature DB >> 11095983

Molecular characterization of a Siglec8 variant containing cytoplasmic tyrosine-based motifs, and mapping of the Siglec8 gene.

G Foussias1, G M Yousef, E P Diamandis.   

Abstract

Through efforts to investigate the CD33-like subgroup of sialic acid binding immunoglobulin-like lectins (Siglecs), which are believed to be located on chromosome 19q13.4, we have identified the precise genomic region containing the Siglec8 gene. It is located on chromosome 19q13.4, approximately 330 kb downstream of the Siglec9 gene. Further, we have identified a novel Siglec8 variant, named Siglec8-Long (Siglec8-L), which differs in its last two exons from the previously published mRNA sequence of Siglec8 (GenBank Accession No. AF195092). Both Siglec8 and Siglec8-L are comprised of seven exons, of which the first five are identical, followed by marked differences in exon usage and mRNA splicing. The 499 amino acid protein encoded by the Siglec8-L open reading frame has a molecular weight of 54 kDa. Like the other members of the CD33-like subgroup of Siglecs, except for the previously published Siglec8, Siglec8-L also contains the two tyrosine-based motifs that have been found to recruit both SH2 domain-containing tyrosine and inositol phosphatases. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095983     DOI: 10.1006/bbrc.2000.3866

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  Siglecs in the immune system.

Authors:  P R Crocker; A Varki
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

2.  Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.

Authors:  Jeremy A O'Sullivan; Daniela J Carroll; Yun Cao; Adriano N Salicru; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-07-20       Impact factor: 10.793

Review 3.  Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.

Authors:  Takumi Kiwamoto; Norihito Kawasaki; James C Paulson; Bruce S Bochner
Journal:  Pharmacol Ther       Date:  2012-06-27       Impact factor: 12.310

Review 4.  "Siglec"ting the allergic response for therapeutic targeting.

Authors:  Bruce S Bochner
Journal:  Glycobiology       Date:  2016-02-23       Impact factor: 4.313

5.  Porcine sialoadhesin (CD169/Siglec-1) is an endocytic receptor that allows targeted delivery of toxins and antigens to macrophages.

Authors:  Peter L Delputte; Hanne Van Gorp; Herman W Favoreel; Inge Hoebeke; Iris Delrue; Hannah Dewerchin; Frank Verdonck; Bruno Verhasselt; Eric Cox; Hans J Nauwynck
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

Review 6.  Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors.

Authors:  B S Bochner
Journal:  Clin Exp Allergy       Date:  2009-03       Impact factor: 5.018

Review 7.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 8.  Eosinophil and mast cell Siglecs: From biology to drug target.

Authors:  Jeremy A O'Sullivan; Alan T Chang; Bradford A Youngblood; Bruce S Bochner
Journal:  J Leukoc Biol       Date:  2020-01-22       Impact factor: 4.962

9.  Sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating β2-integrin-dependent function in human eosinophils.

Authors:  Daniela J Carroll; Jeremy A O'Sullivan; David B Nix; Yun Cao; Michael Tiemeyer; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-09-06       Impact factor: 10.793

Review 10.  Glycobiology of Eosinophilic Inflammation: Contributions of Siglecs, Glycans, and Other Glycan-Binding Proteins.

Authors:  Jeremy A O'Sullivan; Daniela J Carroll; Bruce S Bochner
Journal:  Front Med (Lausanne)       Date:  2017-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.